Building on a successful collaboration, Adalvo and Libbs extend their partnership to bring a high-quality, affordable central nervous system treatment to patients across Brazil.
Zug, Switzerland, 31st August: Adalvo today announced the expansion of its strategic partnership with Libbs Farmacêutica, one of Brazil's leading pharmaceutical companies, with the signing of a new asset in the central nervous system (CNS) therapeutic area for the Brazilian market.
The agreement builds on the established and successful relationship between the two companies, deepening a partnership designed to widen access to high-quality, affordable medicines for the Brazilian population. It reflects the shared ambition of both partners: pairing Adalvo's differentiated development and regulatory capability with Libbs's strong commercial presence and deep understanding of the Brazilian healthcare market.
CNS conditions represent a significant and growing area of unmet need. By bringing this asset to Brazil, Adalvo and Libbs aim to expand treatment options and improve access for the patients who need them.
"We are delighted to expand our partnership with Libbs, a company that shares our commitment to quality and to widening patient access. This new CNS asset reflects the strength of what we can achieve together, and our shared determination to bring high-quality, affordable medicines to the people of Brazil. I am proud of what both teams continue to build."
“This new agreement reinforces the trust built over time and the continuity of a partnership driven by a shared commitment to expanding access to high-quality healthcare treatments. For Libbs, it also represents another step forward in our portfolio diversification strategy, bringing solutions that address important patient needs and expand the therapeutic options available to people in Brazil,” said Anna Guembes, Director of Innovation and Business Development at Libbs.
This partnership reflects Adalvo's commitment to advancing high-quality, differentiated medicines and expanding treatment options for patients through strong local partnerships in key markets worldwide.